NEWS

Ny rapport fra Roche: Fremtiden er persontilpasset – men når kommer fremtiden?

Category: Business and Investment News

Persontilpasning har alltid vært et ideal i medisinsk behandling. Å gi hver enkelt pasient den beste behandlingen krever at all relevant informasjon tas i bruk. Ved bruk av moderne teknologi som stordataanalyser og kunstig intelligens blir det mulig å finne sam- menhenger og mønstre som ikke er synlige for mennesker. Teknologien lager hypoteser og trekker […]

Source: AmCham

Published: October 14, 2019

HealthTalk: Helse-Norge må gjennom en kulturell hestekur

Category: Business and Investment News

Her er tusenmilliarderkronerspørsmålet; Hvordan skal Norge klare å bygge en stor og internasjonalt orientert helsenæring på linje med våre nordiske naboer og samtidig skape et bedre og mer bærekraftig helsevesen? Dette var nøkkelspørsmålet som ble stilt på Arendalsukas kanskje viktigste event – hvor American Chamber of Commerce var vertskap. Timingen for å stille dette spørsmålet […]

Source: HealthTalk

Government: English Summary Version of Whitepaper on the Health Industry Released

Category: Business and Investment News

The government recently released the English version of its recent Whitepaper on the Health Industry. A full copy of the whitepaper can be downloaded HERE.

Source: regjeringen.no

Published: June 11, 2019

Government: Norway joins European collaboration for cross-border access to genomic data

Category: Business and Investment News

Norway now joins an ambitious and extensive genomics collaboration with other European countries. The collaboration will benefit Norwegian research, Norwegian health care and Norwegian patients. The goal of this European collaboration is to improve the research quality. The data can contribute to better prevention, earlier and easier diagnostics, less side effects and more precise prognosis through personalized medicine.  – There is a huge potential for knowledge and medical treatment in genomics. Health […]

Source: regjeringen.no

Published: June 6, 2019

Reuters: Lilly’s combo therapy succeeds in late-stage lung cancer study

Category: Business and Investment News

Eli Lilly and Co’s combination cancer treatment met the main goal of a late-stage clinical trial testing it on patients with a form of lung cancer, the drugmaker announced on Tuesday. Previously untreated patients with metastatic non-small cell lung cancer taking a combination of Lilly’s Cyramza and Roche’s erlotinib went longer before their disease started […]

Source: Reuters

Published: March 12, 2019